The findings of a recent study recommended that Alpha-Glutamyl-Tryptophan can be used in the complex treatment of chronic atrophic gastritis linked with Helicobacter pylori (H. pylori) and for primary prophylaxis of gastric cancer.  In order to assess the efficacy of Alpha-Glutamyl-Tryptophan vs. control group (placebo) as a cytoprotector as part of the complicated treatment for chronic atrophic H. pylori-linked gastritis, this study was carried out.

A total of 121 participants with persistent atrophic H. pylori-related gastritis were incorporated. Blood tests called "Gastropanel" were done before and after the treatment, along with stomach endoscopies, which included biopsies of the atrophied mucosa for histological analysis, a rapid urease test for the identification of H. pylori, and daily pH-metry. Following H. pylori elimination, the study medicine (n = 61) or placebo (n = 60) were given twice daily for 28 days, once in the morning 20–30 minutes before meals and once in the evening just before bedtime.

The consumption of alpha-glutamyl tryptophan is linked to a considerable increase in the pH-metry acidity index, a rise in the ratio of pepsinogen I to pepsinogen II, a reduction in the amount of gastrin-17, and an elevation in the number of glands per 1 mm2 of the gastric mucosa. When used to treat chronic atrophic H. pylori-related gastritis, Alpha-Glutamyl-Tryptophan exhibited a more potent regeneration effect than the placebo and facilitated the return of the stomach's ability to produce acid and pepsin.